Skip to main content

The Alden Keene Cause Marketing Stock Index Dramatically Outperforms Other Indices

There are stock indexes galore; the Dow, S&P 500, the NASDAQ Composite, the Wilshire 5000, the FTSE, and hundreds more. But how would an index of the stocks of companies that do a meaningful amount of cause marketing perform compared to those well-known indexes? Pretty well, as it turns out.

I first floated the idea of a stock index that would track companies that do cause marketing back in 2009. I tried to figure out Yahoo Pipes so that I could put the feed right into this blog. But alas sometimes the geek gene does fall pretty far from the tree.

So I talked to programmers to see if I could find someone who could do the same, but it was always more than I was willing to pay.

Finally, last week I hired a MBA student to do it all in a spreadsheet, and what do you know but that over the last 15 years a basket of 25 cause marketing stocks dramatically outperforms the Dow, the S&P 500, the NASDAQ Composite, and the Wilshire 5000.

The index, which I call the Alden Keene Cause Marketing Stock Index, or the ‘Keene’ for short, outperformed all those other major indices over the last 15 years. From January 1, 1997 to Jan 1, 2013 the Keene’s total growth rate was 342.21%. The Wilshire 5000 was the best performing of the other indices that we tracked and its total growth rate was 167.68%, less than half the growth of the Keene.

What does that mean in dollars and cents?

Well, if on January 1, 1997 you put $1,000 each into index funds that invest in the Dow, the S&P 500, the NASDAQ Composite, the Wilshire 5000, and the Keene, on January 1, 2013 you would have $2032.18 in your Dow fund, $1925.35 in your S&P fund, $2676.82 in your Wilshire fund, $2392.46 in your NASDAQ fund, and $4422.07 in your Keene fund.

The Keene also trounces the other indices in other time frames as well. These numbers don't include any trading costs and they assume you reinvest all dividends.

I don’t have the beta ratios yet, but in the down years of 2000 and 2001, the Keene lost less money than the other indices in the comparison. In the down years of 2002 and 2008, the Keene lost less money than all but one other of the comparison indices.

Beta is a ratio that gives an indication of how much risk you’re taking on when you buy stock(s).

Not surprisingly, since this is cause marketing we’re talking about, most of the companies face the consumer, like General Mills and Campbell’s. But not all. Deere is in the Keene. So are tech brands Adobe and HP.

The stocks in the Keene index were developed based on two major ‘screens.’ First companies were screened for their commitment to corporate social responsibility, including corporate citizenship, governance, and workplace practices. Then companies were screened for their activity as cause marketers. The result is a concentrated index of the stocks of 25 companies that have a reputation for walking their talk when it comes to CSR and cause marketing. 

And, returning outsized growth to their stockholders!

Comments

David Hessekiel said…
Fascinating Paul -- so when are you going to reveal the list? DH

Popular posts from this blog

Chili’s and St. Jude Children’s Research Hospital

I was in Chili’s today and I ordered their “Triple-Dipper,” a three appetizer combo. While I waited for the food, I noticed another kind of combo. Chili’s is doing a full-featured cause-related marketing campaign for St. Jude Children’s Research Hospital. There was a four-sided laminated table tent outlining the campaign on the table. When the waitress brought the drinks she slapped down Chili’s trademark square paper beverage coasters and on them was a call to action for an element of the campaign called ‘Create-A-Pepper,’ a kind of paper icon campaign. The wait staff was all attired in black shirts co-branded with Chili’s and St. Jude. The Create-A-Pepper paper icon could be found in a stack behind the hostess area. The Peppers are outlines of Chili’s iconic logo meant to be colored. I paid $1 for mine, but they would have taken $5, $10, or more. The crayons, too, were co-branded with the ‘Create-A-Pepper’ and St. Jude’s logos. There’s also creatapepper.com, a microsite, but again wi...

Part 2: How Chili's Used Cause-Related Marketing to Raise $8.2 million for St. Jude

[Bloggers Note: In this second half of this post I discuss the nuts and bolts of how Chili's motivates support from its employees and managers and how St. Jude 'activates' support from Chili's. Read the first half here.] How does St. Jude motivate support from Chili’s front line employees and management alike? They call it ‘activation’ and they do so by the following: They share stories of St. Jude patients who were sick and got better thanks to the services they received at the hospital. Two stories in particular are personal for Chili’s staff. A Chili’s bartender in El Dorado Hills, California named Jeff Eagles has a younger brother who was treated at St. Jude. In both 2005 and 2006 Eagles was the campaign’s biggest individual fundraiser. John Griffin, a manager at the Chili’s in Conway, Arkansas had an infant daughter who was treated for retinoblastoma at St. Jude. They drew on the support Doug Brooks… the president and CEO of Brinker International, Chili’s parent co...

Batting Your Eyelashes at Prescription Drug Cause Marketing

I’m a little chary about making sweeping pronouncements, but I believe I've just seen the first cause marketing promotion in the U.S. involving a prescription drug. The drug is from Allergan and it’s called Latisse , “the first and only FDA-approved prescription treatment for inadequate or not enough eyelashes.” The medical name for this condition is hypotrichosis. Latisse is lifestyle drug the way Viagra or Propecia are. That is, no one’s going to die (except, perhaps, of embarrassment) if their erectile dysfunction or male pattern baldness or thin eyelashes go untreated. Which means the positioning for a product like Latisse is a little tricky. Allergan could have gone with the sexy route as with Viagra or Cialis and showed lovely women batting their new longer, thicker, darker eyelashes. But I’ll bet that approach didn’t test well with women. (I’m reminded of a joke about the Cialis ads from a comedian whose name I can’t recall. He said, “Hey if my erection lasts longer than ...